Sickle cell disease trials recruiting in Alabama

All Sickle cell disease trials nationally

Cities in Alabama

Recruiting trials in Alabama

• A Long-term Follow-up Study in Patients Who Received BEAM-101
  NCT07373639 · Phase: Not specified · Ages: 14 Years to 37 Years · Sex: All (male and female) · Alabama: Birmingham
• A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
  NCT07187973 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham
• A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
  NCT05431088 · Phase: Phase 2, Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · Alabama: Mobile
• A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
  NCT06546670 · Phase: Phase 1, Phase 2 · Ages: 12 Years to 55 Years · Sex: All (male and female) · Alabama: Birmingham
• A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
  NCT06609226 · Phase: Phase 3 · Ages: 2 Years and older · Sex: All (male and female) · Alabama: Birmingham
• A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
  NCT06481306 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham
• A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
  NCT06612268 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · Alabama: Birmingham, Mobile
• A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
  NCT06439082 · Phase: Phase 3 · Ages: 12 Years to 100 Years · Sex: All (male and female) · Alabama: Birmingham
• Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT)
  NCT06071377 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham
• Cognitive Remediation Intervention to Prepare for Transition of Care
  NCT05336201 · Phase: Phase 2 · Ages: 10 Years to 18 Years · Sex: All (male and female) · Alabama: Birmingham
• Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
  NCT06941389 · Phase: Not specified · Ages: 3 Years to 20 Years · Sex: All (male and female) · Alabama: Birmingham
• Early Life Exposures Among Children With Sickle Cell Disease
  NCT05377372 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 50 Years · Sex: Female · Alabama: Birmingham
• HPC Offered for PRESERVE Expansion
  NCT07145411 · Phase: Not specified · Ages: 12 Years to 80 Years · Sex: All (male and female) · Alabama: Birmingham
• Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
  NCT06374238 · Phase: Not applicable (e.g. observational or device study) · Ages: 16 Years to 30 Years · Sex: All (male and female) · Alabama: Mobile
• Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease
  NCT06385886 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham
• Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
  NCT04657822 · Phase: Phase 4 · Ages: 6 Months to 100 Years · Sex: All (male and female) · Alabama: Birmingham
• SCD Stem Cell Mobilization and Apheresis Using Motixafortide
  NCT06442761 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham
• The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
  NCT06975865 · Phase: Phase 3 · Ages: 10 Years to 65 Years · Sex: All (male and female) · Alabama: Birmingham